Relationship Between CYP2C19 Loss-of-Function Polymorphism and Platelet Reactivities With Clopidogrel Treatment in Japanese Patients Undergoing Coronary Stent Implantation

Tomoyuki Nakata, MD; Masatoshi Miyahara, MD; Kaname Nakatani, MD; Hideo Wada, MD; Takashi Tanigawa, MD; Fumihiko Komada, MD; Kozo Hoshino, MD; Toshikazu Aoki, MD; Yuki Nishimura, PhD; Satoshi Tamaru, MD; Masaaki Ito, MD; Masakatsu Nishikawa, MD

Background: CYP2C19 loss-of-function genotype (*2 and/or *3 alleles) is related to low responsiveness to clopidogrel, which is a risk factor for ischemic cardiac events. The contribution of these genotypes to platelet reactivity in Japanese patients in a steady state receiving dual antiplatelet therapy after coronary stenting was evaluated.

Methods and Results: A total of 155 Japanese patients were classified according to their CYP2C19 loss-of-function genotype. Platelet reactivity was assayed by plasma levels of soluble P-selectin and platelet-derived microparticles, light transmittance aggregometry induced by ADP (ADP-LTA), shear stress-induced platelet aggregometry, vasodilator-stimulated phosphoprotein phosphorylation (VASP) index and the VerifyNow-P2Y12 assay. Linear and logistic regression models were used to assess the associations between CYP2C19 loss-of-function genotype and high on-treatment platelet reactivity. In total, 62 patients (40.0%) were extensive metabolizers (EMs), 70 (45.2%) were intermediate metabolizers (IMs) and 23 (14.8%) were poor metabolizers (PMs). ADP-specific assays (ADP-LTA, the VASP index and VerifyNow-P2Y12) differed according to CYP2C19 genotype, with a significant gene-dose effect (PMs > IMs > EMs). CYP2C19 loss-of-function carrier status was associated with more frequent high platelet reactivity. CYP2C19 loss-of-function genotype alone could explain 12.2%, 14.3%, and 14.7% of the variability in the ADP-LTA, VASP and VerifyNow-P2Y12 assays, respectively.

Conclusions: CYP2C19 loss-of-function genotype is associated with more frequent high platelet reactivity, as assessed by ADP-specific platelet function tests, in Japanese patients. (Circ J 2013; 77: 1436–1444)

Key Words: Clopidogrel; CYP2C19; Platelet reactivity; Stent; Thrombosis

Dual antiplatelet therapy (DAP) using aspirin and clopidogrel is the most common management strategy for patients who have undergone percutaneous coronary intervention (PCI) with stent implantation. Several studies have suggested that being a low-responder to clopidogrel is associated with a poor clinical outcome after acute coronary syndrome (ACS), particularly after PCI. To monitor the antiplatelet effects, several laboratory tests are available, including platelet activation markers (such as plasma levels of soluble P-selectin and platelet-derived microparticles (PMPs)), platelet vasodilator-stimulated phosphoprotein (VASP) phosphorylation status, and platelet aggregation tests, such as light transmittance aggregometry (LTA), shear stress-induced platelet aggregometry (SIPA) and the VerifyNow assay. Differences in assays, agonist concentrations, and cut-off values have contributed to the variability in the reported prevalence of a low response to clopidogrel. Elevated platelet aggregation, indicating a low, impaired response to clopidogrel, has been associated with recurrent ischemic events. The whole blood VerifyNow-P2Y12 test is a rapid test that uses ADP to stimu-
late platelets in the presence of prostaglandin E1, thus making the assay more sensitive to the activity of P2Y12.4

The mechanisms leading to a low response to clopidogrel are not fully understood and are probably multifactorial.12,13 Clopidogrel is an inactive prodrug that requires several biotransformation steps to become an active inhibitor of the platelet ADP-P2Y12 receptor. After intestinal absorption, clopidogrel is metabolized in the liver by cytochrome P-450 (CYP) isozymes, including CYP2C19, 3A4/5, 1A2, 2B6 and 2C9.14–16 A loss-of-function polymorphism in CYP2C19, known as the CYP2C19*2 and CYP2C19*3 allelic variants, has been associated with a higher level of ADP-induced platelet aggregation values in clopidogrel-treated patients, and is consequently a higher risk of major adverse cardiovascular events, including stent thrombosis.14–19 These CYP2C19 loss-of-function genotypes are more frequent in Asian (13–23%) than in Caucasian (1–6%) populations.20–23 Therefore, this genomic polymorphism may be clinically more important in Japanese patients.

In many studies, laboratory assessment of clopidogrel responsiveness has been performed using only one platelet reactivity test during the acute phase before coronary stenting. The response to clopidogrel is highly dynamic during the acute phase of myocardial infarction (MI) after clopidogrel loading, just before PCI, and most patients improve their on-treatment platelet reactivity significantly during the chronic period (1 month) after PCI and clopidogrel administration.24 The thrombotic condition of the coronary artery after resolving ischemia and platelet activation by stent implantation could be stabilized, and the isolated low responsiveness to the drug would be obtained in the chronic phase. We evaluated the relationship between CYP2C19 loss-of-function genotype and various platelet reactivity tests in Japanese patients in the chronic phase receiving DAP after coronary stenting. To elucidate the most appropriate method of quantifying the level of residual platelet reactivity, we examined several methods simultaneously, which included measurement of platelet activation markers (soluble P-selectin and PMPs) and platelet VASP phosphorylation status, and platelet aggregation tests (ADP-LTA, SIPA and VerifyNow-P2Y12 assays). The relative contribution of each CYP2C19 loss-of-function genotype to the interindividual variability in on-treatment platelet reactivity was also determined.

Methods

Patient Population and Study Design

This was a prospective observational study performed at multiple hospitals from December 2008 to April 2011. The Ethics Committee of Mie University Hospital approved the study protocol (No. 986) in accordance with the Declaration of Helsinki, and all patients gave their written informed consent for participation.

Patients were eligible for enrolment if they had stable coronary artery disease requiring PCI and had no known allergy to aspirin or clopidogrel; patients with active bleeding disease, cerebral infarction with embolization from the heart, taking anticoagulation agents, such as warfarin, and antiplatelet agents other than aspirin and clopidogrel before the surgical operation were excluded. Patients who were not eligible (as determined by the responding physician) were also excluded. For the VerifyNow-P2Y12 assay, the patients’ inclusion criteria were as follows: hematocrit, 33–52%; platelet count, 119,000–502,000/mm³; total cholesterol level, 98–316 mg/dl; triglycerides level, 41–824 mg/dl; and fibrinogen, 171–599 mg/dl. We defined diabetes mellitus as >6.5% of HbA1c or treatment with insulin or hypoglycemic medication. Patients with estimated glomerular filtration rate (eGFR) <60 ml·min⁻¹·1.73 m⁻² for 3 months were defined as having chronic kidney disease. Blood sampling for the assessment of clopidogrel response was performed once from 14 to 28 days after coronary stenting.

Platelet Function Assays

Blood samples for platelet function analysis were drawn by atrumatic venipuncture of the antecubital vein using a 21-gauge needle. The initial blood sample drawn was measured for blood chemistry to measure any platelet activation induced by needle puncture. Blood was then collected into a Vacuette® (Greiner bio-one International, Kremsmünster, Austria) containing 3.2% sodium citrate, or Neotube® (Nipro, Osaka, Japan) containing ACD-A and EDTA 2Na. Platelet function tests were completed within 2 h of blood sampling. To avoid inter-hospital variability, 2 operators performed each platelet function test in the Mie University Hospital, within 2 h of blood sampling; the operators were blinded to the clinical
Circulation Journal Vol.77, June 2013
NAKATA T et al.

VerifyNow-P2Y12 platelet reaction units (PRU) were measured by a turbidimetric method (Accumetrics Inc, San Diego, CA, USA), based on an optical detection system as an increase in light transmittance. The test cartridge contained a lyophilized preparation of human fibrinogen-coated beads, platelet agonist, preservative and buffer. ADP (20 μmol/L) was used to maximally activate the platelets by binding to the P2Y1 and P2Y12 platelet receptors, and PGE1 was used to suppress the ADP-induced P2Y1-mediated increase in intracellular calcium levels, and thereby reduce the activation contributed by P2Y1 and thus increase assay sensitivity.

Enzyme-linked immunosorbent assay kits were used to determine the plasma levels of PMPs and soluble P-selectin, using the protocols provided by the manufacturers (JIMRO PDMP ELISA kit, Otsuka Pharmaceutical Inc, Tokyo, Japan and Human sP-selectin ELISA Kit, Invitrogen Co, Carlsbad, CA, USA).

CYP2C19 Genotyping
A QIAamp Blood Kit (Qiagen, Hilden, Germany) was used to isolate genomic DNA. CYP2C19 polymorphisms were analyzed for the nonfunctional alleles *2 and *3 by identifying 2 polymorphic positions: 681G>A in exon 5 and 636G>A in exon 4, respectively. The region including the polymorphisms was amplified by polymerase chain reaction (PCR) and genotyping was performed using the SNaPshot Multiplex Kit.

Table 1. Baseline Characteristics of the Study Population

<table>
<thead>
<tr>
<th></th>
<th>Total (n=155)</th>
<th>CYP2C19 loss-of-function genotype</th>
<th>P value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, years</td>
<td>69.4±10.2</td>
<td>69.4±10.4</td>
<td>68.8±10.5</td>
</tr>
<tr>
<td>Sex, F/M</td>
<td>45/110</td>
<td>13/49</td>
<td>27/43</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>24.0±3.7</td>
<td>24.3±3.7</td>
<td>24.0±4.0</td>
</tr>
<tr>
<td>Previous history, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Myocardial infarction</td>
<td>39 (25.2)</td>
<td>11 (17.7)</td>
<td>22 (31.4)</td>
</tr>
<tr>
<td>Cerebral infarction</td>
<td>4 (2.6)</td>
<td>1 (1.6)</td>
<td>2 (2.9)</td>
</tr>
<tr>
<td>Risk factors, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Current smoker</td>
<td>14 (9.0)</td>
<td>7 (11.3)</td>
<td>4 (5.7)</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>69 (44.5)</td>
<td>32 (51.6)</td>
<td>27 (38.6)</td>
</tr>
<tr>
<td>Dyslipidemia</td>
<td>110 (71.0)</td>
<td>47 (75.8)</td>
<td>48 (68.6)</td>
</tr>
<tr>
<td>Hypertension</td>
<td>96 (61.9)</td>
<td>38 (61.3)</td>
<td>42 (60.0)</td>
</tr>
<tr>
<td>Obesity (BMI &gt;25)</td>
<td>48 (31.0)</td>
<td>23 (37.1)</td>
<td>21 (30.0)</td>
</tr>
<tr>
<td>Chronic kidney disease</td>
<td>6 (3.9)</td>
<td>2 (3.2)</td>
<td>3 (4.3)</td>
</tr>
<tr>
<td>No. of risk factors, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1</td>
<td>36 (23.2)</td>
<td>11 (17.7)</td>
<td>21 (30.0)</td>
</tr>
<tr>
<td>2</td>
<td>39 (25.2)</td>
<td>15 (24.2)</td>
<td>15 (21.4)</td>
</tr>
<tr>
<td>&gt;3</td>
<td>67 (43.2)</td>
<td>32 (51.6)</td>
<td>26 (37.1)</td>
</tr>
<tr>
<td>Medication, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Aspirin</td>
<td>153 (98.7)</td>
<td>62 (100)</td>
<td>68 (97.1)</td>
</tr>
<tr>
<td>Statin</td>
<td>98 (63.2)</td>
<td>43 (69.4)</td>
<td>39 (55.7)</td>
</tr>
<tr>
<td>Proton-pump inhibitor</td>
<td>49 (31.6)</td>
<td>24 (38.7)</td>
<td>22 (31.4)</td>
</tr>
<tr>
<td>H2 receptor antagonist</td>
<td>24 (15.5)</td>
<td>6 (9.7)</td>
<td>13 (18.6)</td>
</tr>
<tr>
<td>CYP2C19, n (%)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EM</td>
<td>62 (40.0)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>IM</td>
<td>70 (45.2)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PM</td>
<td>23 (14.8)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

BMI, body mass index; EM, extensive metabolizer; IM, intermediate metabolizer; PM, poor metabolizer.
CYP2C19 Polymorphisms and High Platelet Reactivity

Statistical Analysis

The sample size was calculated to detect whether the patients with CYP2C19 loss-of-function genotype had a 2-fold or larger increase in the occurrence of high platelet reactivity (25%) as compared with CYP2C19 wild-type patients, according to a previous report. To demonstrate such a difference, the inclusion of 152 patients was required to yield 80% power with an alpha risk error of 0.05, as the frequency of CYP2C19 *1 allele is 60% in Japanese patients.

Continuous variables are presented as mean±standard deviation.
The baseline characteristics of the patients (n=155) was as follows: 62 patients (40.0%) were CYP2C19 wild-type (*1/*1) homozygotes; 11 patients (7.1%) were CYP2C19*2 homozygotes (*2/*2); 43 patients (27.7%) were CYP2C19*2 heterozygotes (*1/*2); 2 patients (1.3%) were CYP2C19*3 homozygotes (*3/*3); 27 patients (17.4%) were CYP2C19*3 heterozygotes (*1/*3); and 10 patients (6.5%) had both CYP2C19*3 and CYP2C19*2 mutant alleles (*2/*3). The patients could be divided into 3 groups according to their CYP2C19 genotype: 62 (40.0%) EMs (CYP2C19*1/*1), 70 (45.2%) IMs (CYP2C19*1/*2 and CYP2C19*1/*3) and 23 (14.8%) PMs (CYP2C19*2/*2, CYP2C19*2/*3, and CYP2C19*3/*3). These data indicate that CYP2C19 loss-of-function genotypes in Japanese patients are more frequent than in Caucasians.17–20 The baseline characteristics of the patients were compared among the three CYP2C19 genotype groups (Table 1). There were no significant differences in any of the parameters, although a trend was present indicating that females were more frequently IMs than males (females 60.0% vs. males 39.3%, P=0.060).

The relationships between CYP2C19 genotype and various platelet reactivity tests (soluble P-selectin and PMPs; platelet VASP index, SIPA, ADP (20 μmol/L)-LTA and VerifyNow-P2Y12) were considered as high platelet reactivity (clopidogrel low-responder) in this study. The corresponding 4Q cut-off values were determined by ROC curve analysis: 61.6% for the VASP index provided 47% sensitivity and 80% specificity, a positive predictive value of 38% and a negative predictive value of 85%. The cut-off value of 302 PRU for the VerifyNow-P2Y12 assay was determined to provide a sensitivity of 70%, specificity of 88%, a positive predictive value of 64% and a negative predictive value of 91%. High platelet reactivity with a 4Q value ≥62% by ADP-LTA was detected in 5 cases (8.1%) among the EMs (n=62), 14 (20.0%) among the IMs (n=70), 24 (50.0%) among the PMs (n=48), and 16 (32.0%) among the healthy volunteers (n=50).

### Results

The clinical characteristics and polymorphisms of CYP2C19 in the 155 patients enrolled in this study (Figure 1) are shown in Table 1. The distribution of CYP2C19 polymorphisms (n=155) was as follows: 62 patients (40.0%) were CYP2C19 wild-type (*1/*1) homozygotes; 11 patients (7.1%) were CYP2C19*2 homozygotes (*2/*2); 43 patients (27.7%) were CYP2C19*2 heterozygotes (*1/*2); 2 patients (1.3%) were CYP2C19*3 homozygotes (*3/*3); 27 patients (17.4%) were CYP2C19*3 heterozygotes (*1/*3); and 10 patients (6.5%) had both CYP2C19*3 and CYP2C19*2 mutant alleles (*2/*3). The patients could be divided into 3 groups according to their CYP2C19 genotype: 62 (40.0%) EMs (CYP2C19*1/*1), 70 (45.2%) IMs (CYP2C19*1/*2 and CYP2C19*1/*3) and 23 (14.8%) PMs (CYP2C19*2/*2, CYP2C19*2/*3, and CYP2C19*3/*3). These data indicate that CYP2C19 loss-of-function genotypes in Japanese patients are more frequent than in Caucasians.17–20 The baseline characteristics of the patients were compared among the three CYP2C19 genotype groups (Table 1). There were no significant differences in any of the parameters, although a trend was present indicating that females were more frequently IMs than males (females 60.0% vs. males 39.3%, P=0.060).

The relationships between CYP2C19 genotype and various platelet reactivity tests (soluble P-selectin and PMPs; platelet VASP index, SIPA, ADP (20 μmol/L)-LTA and VerifyNow-P2Y12) were assessed (Figure 2). These laboratory tests were performed at 22.5±5.4 days after clopidogrel administration. ADP-LTA, VASP index and VerifyNow-P2Y12 all increased according to the degree of CYP2C19 loss-of-function genotype (PMs>IMs>EMs), indicating a gene-dose effect. Soluble P-selectin, PMPs and SIPA results were not related to CYP2C19 genotype, although SIPA in PMs was significantly higher than in EMs. The 24 patients with mild anemia [Hb ≥11 g/dl, 14 females] at blood sampling could not be assessed by VerifyNow-P2Y12, because the apparatus could only assay the aggregation in blood with Hb ≥12.0 g/dl. In the ADP-specific platelet function tests, including ADP-LTA, the VASP index or the VerifyNow-P2Y12 assay, there was a statistically significant difference among the three genotype groups (P<0.001, Kruskal-Wallis test). CYP2C19 loss-of-function genotyping explained 12.2%, 14.3% and 14.7% of the interindividual variability in the ADP-LTA, VASP index and VerifyNow-P2Y12 assay, respectively, compared with 15.3%, 23.4% and 26.2% when clinical factors were included (Table 2). The clinical variables independently associated with the magnitude of platelet reactivity were age, male sex and diabetes mellitus (HbA1c ≥6.5% or being treated as diabetic). There was no association between body mass index, chronic kidney disease or proton-pump inhibitors and the magnitude of platelet reactivity.

### Table 2. Variability in Platelet Reactivity Assayed by ADP (20 μmol/L)-LTA, VASP Index and VerifyNow-P2Y12 Assay

<table>
<thead>
<tr>
<th></th>
<th>ADP-LTA</th>
<th>VASP</th>
<th>VerifyNow-P2Y12</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R²</td>
<td>P value</td>
<td>R²</td>
</tr>
<tr>
<td>CYP2C19 loss-of-function</td>
<td>12.2%</td>
<td>&lt;0.001</td>
<td>14.3%</td>
</tr>
<tr>
<td>Clinical variables*</td>
<td>9.5%</td>
<td>0.004</td>
<td>14.8%</td>
</tr>
<tr>
<td>CYP2C19 loss-of-function + clinical variables</td>
<td>15.3%</td>
<td>&lt;0.001</td>
<td>23.4%</td>
</tr>
<tr>
<td>P for change†</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
<td>&lt;0.001</td>
</tr>
</tbody>
</table>

Percentage of variability in platelet reactivity explained was defined as the coefficient determination (R²), 100%.

*Sex, age and diabetes mellitus were significantly associated with platelet reactivity in univariate analysis (P<0.1).
†P value for the change in R² when adding clinical variables to CYP2C19 loss-of-function genotype.

LTA, light transmittance aggregometry; VASP, platelet vasodilator-stimulated phosphoprotein.
and 13 (56.5%) among the PMs (n=23). High platelet reactivity with a 4Q value ≥61.6% by the VASP index was detected in 8 cases (12.9%) among the EMs (n=62), 18 (25.7%) among the IMs (n=70), and 13 (56.5%) among the PMs (n=23). High platelet reactivity with a 4Q value ≥302 PRU by the VerifyNow-P2Y12 assay was detected in 4 cases (7.3%) among the EMs (n=55), 18 (32.7%) among the IMs (n=55), and 11 (52.4%) among the PMs (n=21). In each ADP-specific platelet function test, the order of frequency of high platelet reactivity by DAP therapy was PMs > IMs > EMs.

To determine predictors of high platelet reactivity, multivariate logistic analysis was performed, including \( CYP2C19 \) loss-of-function genotype, in addition to clinical variables (male gender, age, eGFR, and diabetes mellitus) that were associated with the platelet reactivity in multivariate linear regression. \( CYP2C19 \)-PMs and \( CYP2C19 \)-IMs were compared with \( CYP2C19 \)-EMs. Only PMs predicted the high platelet reactivity in each ADP-specific assay, but a trend was observed regarding IMs (Figure 4). PMs had an approximately 9 to 15 times increase in the occurrence of high platelet reactivity as compared with EMs; this association appeared to be stronger for patients with IMs.
Discussion
In the present study group, the laboratory response to clopidogrel in the stable phase after clopidogrel administration and stent implantation was assessed to evaluate the relationship between clopidogrel response and \textit{CYP2C19} loss-of-function genotype. Among various tests examined in this study, ADP-LTA, platelet VASP and VerifyNow-P2Y12 were strongly affected by \textit{CYP2C19} loss-of-function genotype. Bouman et al reported that ADP (20 \text{μmol/L})-LTA, the VASP index and VerifyNow-P2Y12 assay correlate with the in vitro plasma levels of the active metabolite of clopidogrel, which is im-
CYP2C19 Polymorphisms and High Platelet Reactivity

important when estimating the relative contribution of CYP2C19 loss-of-function genotype to the generation of the active metabolite. These 3 platelet function tests have been shown to be capable of predicting clinical outcome in PCI patients administered clopidogrel.\(^5,\)\(^6,\)\(^7,\)\(^8\) In the present study, the results of the VerifyNow-P2Y12 assay and VASP assay significantly correlated with those of ADP-LTA, which is considered the gold standard method. A stronger correlation with ADP-LTA was observed with the VerifyNow-P2Y12 assay. The rapidity and ease of use of this method suggest that it might be valuable for point-of-care testing of patients receiving P2Y12 receptor blockers.

We divided post-treatment residual platelet reactivity into quartiles of each platelet function test, and patients in 4Q were defined as clopidogrel low-responders (ie, high platelet reactivity). Our study showed that 4Q values for identifying clopidogrel low-responders among Japanese PCI patients were ≥62% for ADP-LTA, ≥302 PRU for VerifyNow-P2Y12 and ≥61.6% for the VASP index. Using these values, the VerifyNow-P2Y12 assay revealed a higher sensitivity and specificity for detecting high residual platelet reactivity, based on the results from ADP-LTA, which is similar to recent studies.\(^2,\)\(^9,\)\(^7,\)\(^8\) In recent clinical trials,\(^2,\)\(^3,\)\(^5,\)\(^8\) receiver-operating characteristic curves were used to determine the optimal cut-off values for platelet function tests to predict major cardiovascular events after PCI. The POPULAR study\(^8\) suggested that ADP-LTA, VerifyNow-P2Y12 and Plateletnetworks are able to identify patients at higher risk for ischemic cardiac events after PCI. Findings from the present prospective study showed that the optimal cut-off values for ADP (20)\(\mu\)mol/L)-LTA and VerifyNow-P2Y12 were 64.5% and 236 PRU, respectively. There have been several other trials outside of Japan that have associated high residual platelet reactivity with clinical outcome, and the cut-off values based on receiver-operating characteristic analyses were as follows: ADP (5)\(\mu\)mol/L)-LTA, >46%; VerifyNow-P2Y12, >235 PRU; VASP index, >50%. The 4Q value of ≥62% for ADP-LTA obtained from our study is similar to the cut-off value in previous studies, whereas those of ≥61.6% for the VASP index and ≥302 PRU for VerifyNow-P2Y12 were both higher than the cut-off values reported by other investigators outside Japan. Using a VASP index >50%, high residual platelet reactivity would be seen in 45.2% (70/155), comprising 74.3% (52/70) CYP2C19 loss-of-function genotype patients (IM: 34 cases, PM: 18 cases). Using a VerifyNow-P2Y12 assay >235 PRU, a high residual platelet reactivity would be seen in 50.4% (66/131), which contained 74.2% (49/66) CYP2C19 loss-of-function genotype patients (IM: 35 cases, PM: 14 cases). The reason for the discrepancy in cut-off points between our data and previous Caucasian studies remains unknown, but may be partly explained by the high frequency of the CYP2C19 loss-of-function variants *2 and *3 in the Japanese population.

CYP2C19 polymorphisms are not associated with platelet aggregation at baseline,\(^16\) which suggests that CYP2C19 is the major genetic mediator of the laboratory clopidogrel response. Our study results suggest that the relative contribution of CYP2C19 loss-of-function genotype to the variable reactivity in Japanese patients is 2- to 3-fold higher than in Caucasian patients.\(^25\) We found that residual platelet reactivity during clopidogrel treatment was strongly affected by CYP2C19 loss-of-function genotype; the order of the magnitude of the residual platelet reactivity was PM>IM>EM with ADP-LTA, VerifyNow-P2Y12 or the VASP index, indicating a gene-dose effect. The present study shows that in addition to CYP2C19 loss-of-function genotype, clinical variables such as sex, age and diabetes contribute significantly to the degree of platelet reactivity. CYP2C19 loss-of-function alleles were identified as the only significant predictor of high residual platelet activity in each ADP-specific assay. However, clinical variables such as sex, age and diabetes mellitus were not related to the risk of the high platelet reactivity in our study. This might be attributed to the small sample size and the inclusion of the stable patients. The frequency of CYP2C19 loss-of-function alleles is much higher among Asian populations, including Japanese; therefore, a low response to clopidogrel might be potentially more important in those populations. However, the j-Cypher registry\(^5\) shows that the rate of stent thrombosis in Japanese patients is lower than in Caucasian patients. Taken together with the results from the j-Cypher registry, our present study suggests that the cut-off values for platelet function tests of a low response to clopidogrel could differ according to ethnicity and/or country. Other factors, both genetic and nongenetic, that affect the clopidogrel response may also vary between ethnic groups. Global studies in ethnically diverse populations are warranted.

Study Limitations
This was an observational prospective study, and the small study population meant that we could not clarify the relationship between residual platelet reactivity and patients’ outcomes. This study did not determine plasma levels of the active metabolite of clopidogrel, so we could not provide direct evidence of reduced antiplatelet activity by clopidogrel among patients carrying CYP2C19 loss-of-function genotypes. In addition, we did not survey all types of CYP2C19 polymorphisms. A nationwide study enrolling many more high-risk patients should be performed to clarify the relationships among CYP2C19 loss-of-function genotypes, residual platelet reactivity and clinical outcome.

Conclusions
CYP2C19 loss-of-function genotype with the *2 and/or *3 allele is associated with higher residual platelet reactivity, as assessed by ADP-specific platelet function tests, including ADP-LTA, VASP and VerifyNow-P2Y12. The contribution of CYP2C19 loss-of-function genotype to interindividual variability in clopidogrel platelet reactivity in Japanese patients seems to be higher than that of clinical variables.

Acknowledgments
The McLORDD study was an academic research project supported by a research grant from Daiichi Sankyo Company Limited, Tokyo, Japan. The study sponsor was not involved in the study design, or the collection, analysis or interpretation of the data.

Disclosures
Dr Nishikawa M has received honoraria for lectures from Daiichi Sankyo Inc, Sanofi-Aventis, and Otsuka Pharmaceutical Inc. The other authors declare no conflict of interest concerning this study.

References


**Appendix**

The complete list of McLORDD Investigators is as follows: Tomoyuki Nakata, MD; Masaaki Ito, MD; Masatoshi Miyahara, MD; Toshiki Sawai, MD; Akihito Fuji, MD; Muneyoshi Tanimura, MD; Satoshi Ota, MD; Takashi Tanigawa, MD; Tairo Kurita, MD; Toshikazu Aoki, MD; Kozo Hoshino, MD; Takanomi Hashimoto, MD; Shiro Nakamori, MD; Fumihiko Komada, MD; Hitoshi Kimikoto, MD; Masahiko Nakamura, MD; Hideo Wada, MD; Kaname Nakatani, MD; Yuki Nishimura, PhD; Tomomi Yamada, PhD; Satoshi Tamura, MD; Masakatsu Nishikawa, MD, PhD.